Drug intelligence / Profile preview

SHR4640 + furosemide

Development stage
Unknown
Lead developer
Hengrui Pharmaceutical
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular, Subcutaneous
01

Overview

SHR4640 + furosemide is a combination of two pharmaceutical agents. Furosemide is a well-established loop diuretic used to treat edema associated with congestive heart failure, liver disease (cirrhosis), and renal disease (including nephrotic syndrome), as well as hypertension. It acts by inhibiting the reabsorption of sodium and chloride in the loop of Henle and distal renal tubule in the kidney, leading to increased excretion of water and electrolytes such as sodium, chloride, magnesium, potassium, and calcium[1][5][6]. Furosemide is available under several brand names including Lasix and Furoscix. SHR4640 appears to be an investigational or code name for another agent; however, no detailed public information about its mechanism or clinical status was found in these results.

Brand names
LasixDiaqua-2Diaqua2Diaqua 2Lo-AquaFuroscix
Other names
frusemide
02

Targets

URAT1 (Uric Acid Transporter 1)

Beyond the preview

Go deeper on SHR4640 + furosemide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR4640 + furosemide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call